Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in Idiopathic Pulmonary Fibrosis
NCT04419506Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 2 trial of nerandomilast in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Jul 2020; status: completed.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04419506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419506.